Broad-spectrum humanized monoclonal neutralizing antibody against SARS-CoV-2 variants, including the Omicron variant

INTRODUCTION: Therapeutic monoclonal antibodies (mAbs) against the SARS-CoV-2 spike protein have been shown to improve the outcome of severe COVID-19 patients in clinical trials. However, novel variants with spike protein mutations can render many currently available mAbs ineffective. METHODS: We pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Kun, Cai, Jian-Piao, Fan, Xiaodi, Zhang, Xiaojuan, Luo, Cuiting, Tang, Kai-Ming, Shuai, Huiping, Chen, Lin-Lei, Zhang, Ricky Ruiqi, Situ, Jianwen, Tsoi, Hoi-Wah, Wang, Kun, Chan, Jasper Fuk-Woo, Yuan, Shuofeng, Yuen, Kwok-Yung, Zhou, Hongwei, To, Kelvin Kai-Wang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cellular and Infection Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461085/
https://www.ncbi.nlm.nih.gov/pubmed/37645378
http://dx.doi.org/10.3389/fcimb.2023.1213806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461085/
https://www.ncbi.nlm.nih.gov/pubmed/37645378
http://dx.doi.org/10.3389/fcimb.2023.1213806

Ejemplares similares